DK3769753T3 - Fremgangsmåde til fremstilling af sterile oftalmiske vandige suspensioner af nanokrystaller af fluticasonpropionat-form A - Google Patents

Fremgangsmåde til fremstilling af sterile oftalmiske vandige suspensioner af nanokrystaller af fluticasonpropionat-form A Download PDF

Info

Publication number
DK3769753T3
DK3769753T3 DK20186965.8T DK20186965T DK3769753T3 DK 3769753 T3 DK3769753 T3 DK 3769753T3 DK 20186965 T DK20186965 T DK 20186965T DK 3769753 T3 DK3769753 T3 DK 3769753T3
Authority
DK
Denmark
Prior art keywords
nanocrystals
preparation
aqueous suspensions
fluticasone propionate
ophthalmic aqueous
Prior art date
Application number
DK20186965.8T
Other languages
Danish (da)
English (en)
Inventor
Jean-Michel Bukowski
Akshay Nadkarni
José L Boyer
Brigitte Duquesroix-Chakroun
Tomas Navratil
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Application granted granted Critical
Publication of DK3769753T3 publication Critical patent/DK3769753T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK20186965.8T 2019-07-23 2020-07-21 Fremgangsmåde til fremstilling af sterile oftalmiske vandige suspensioner af nanokrystaller af fluticasonpropionat-form A DK3769753T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US201962942551P 2019-12-02 2019-12-02

Publications (1)

Publication Number Publication Date
DK3769753T3 true DK3769753T3 (da) 2022-01-31

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20186965.8T DK3769753T3 (da) 2019-07-23 2020-07-21 Fremgangsmåde til fremstilling af sterile oftalmiske vandige suspensioner af nanokrystaller af fluticasonpropionat-form A

Country Status (23)

Country Link
US (3) US20220241296A1 (enExample)
EP (1) EP3769753B1 (enExample)
JP (2) JP7021301B2 (enExample)
KR (1) KR20220038443A (enExample)
CN (2) CN111821261B (enExample)
AU (1) AU2020317084A1 (enExample)
CA (1) CA3145055A1 (enExample)
CY (1) CY1124930T1 (enExample)
DK (1) DK3769753T3 (enExample)
ES (1) ES2905793T3 (enExample)
HR (1) HRP20220165T1 (enExample)
HU (1) HUE057416T2 (enExample)
LT (1) LT3769753T (enExample)
MD (1) MD3769753T2 (enExample)
MX (1) MX420447B (enExample)
PH (1) PH12022550003A1 (enExample)
PL (1) PL3769753T3 (enExample)
PT (1) PT3769753T (enExample)
RS (1) RS62932B1 (enExample)
SI (1) SI3769753T1 (enExample)
SM (1) SMT202200082T1 (enExample)
TW (1) TWI864053B (enExample)
WO (1) WO2021014348A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3769753T3 (pl) * 2019-07-23 2022-04-04 Nicox Ophthalmics, Inc. Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20060229219A1 (en) 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
US20110105450A1 (en) 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
EP3517541B1 (en) 2012-05-08 2020-07-15 Nicox Ophthalmics, Inc. Polymorphic form of fluticasone propionate
CN104869980A (zh) * 2012-12-17 2015-08-26 葛兰素集团有限公司 用于治疗炎症性病症和/或变应性病症的左卡巴斯汀和糠酸氟替卡松的组合
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑
PL3769753T3 (pl) * 2019-07-23 2022-04-04 Nicox Ophthalmics, Inc. Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu

Also Published As

Publication number Publication date
TWI864053B (zh) 2024-12-01
CN115120557A (zh) 2022-09-30
MD3769753T2 (ro) 2022-04-30
CN111821261B (zh) 2022-07-26
TW202116326A (zh) 2021-05-01
JP7021301B2 (ja) 2022-02-16
CN111821261A (zh) 2020-10-27
US11406596B2 (en) 2022-08-09
WO2021014348A1 (en) 2021-01-28
JP2021017449A (ja) 2021-02-15
HRP20220165T1 (hr) 2022-04-29
SMT202200082T1 (it) 2022-03-21
RS62932B1 (sr) 2022-03-31
CA3145055A1 (en) 2021-01-28
AU2020317084A1 (en) 2022-03-03
CN115120557B (zh) 2024-05-07
MX420447B (es) 2025-02-10
HUE057416T2 (hu) 2022-05-28
EP3769753A1 (en) 2021-01-27
JP7494230B2 (ja) 2024-06-03
PH12022550003A1 (en) 2022-11-14
PT3769753T (pt) 2022-02-15
CY1124930T1 (el) 2023-01-05
ES2905793T3 (es) 2022-04-12
KR20220038443A (ko) 2022-03-28
US20220323352A1 (en) 2022-10-13
EP3769753B1 (en) 2021-11-17
US20220241296A1 (en) 2022-08-04
MX2022000928A (es) 2022-02-22
JP2022062172A (ja) 2022-04-19
LT3769753T (lt) 2022-05-10
SI3769753T1 (sl) 2022-04-29
PL3769753T3 (pl) 2022-04-04
US20210023001A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
IL282101A (en) Determining a correction to a process
DK3769753T3 (da) Fremgangsmåde til fremstilling af sterile oftalmiske vandige suspensioner af nanokrystaller af fluticasonpropionat-form A
DK3672975T3 (da) Kondenserede, heterocykliske derivater som bcl-2-hæmmere til behandling af neoplastiske sygdomme
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
EP3795118A4 (en) NASAL IMPLANT MANUFACTURING PROCESS
EP3972738C0 (en) ELECTROSTATIC AIR FILTER
IL289453A (en) Process for the preparation of ridinilazole and crystalline forms thereof
SI3877395T1 (sl) Industrijski postopek za pripravo visokočistega estetrola
EP3723674A4 (en) RECONFIGURABLE ORTHESIS FOR CORRECTING DEFORMATIONS
EP3776070A4 (en) Tear shaping for refractive correction
IT201900004041A1 (it) Procedimento per la preparazione di un derivato del fulvestrant
EP3849643A4 (en) NOSE SEAL FOR A RESPIRATORY PATIENT INTERFACE
HUE064888T2 (hu) Eljárás alkoxilátok elõállítására
EP3560476A4 (en) FOLDABLE SPRAY CATHETER FOR NASAL CAVITY
IL286078A (en) Process for the preparation of lipidated proteinaceous structures
LT3561056T (lt) Peptidas, skirtas gydyti su amžiumi susijusią geltonosios dėmės degeneraciją
HUE055374T2 (hu) Eljárás Lenvatinib elõállítására
IL282036A (en) Process for preparing imidazole derivatives
FR3033723B1 (fr) Procede de reparation de la denture d'une couronne
EP3705921C0 (en) OPTICAL INTERCONNECTION AND ITS MANUFACTURING PROCESS
EP4036633A4 (en) Ophthalmic lens
KR102238736B9 (ko) 살균필터
MA53146A (fr) Procédé de préparation de suspensions nanocristallines de propionate de fluticasone aqueux ophtalmique stérile
EP3634307C0 (en) Method for corneal transplants
DK4021505T3 (da) Medikament til behandling af infektionssygdomme